Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Latanoprost Versus Fotil

This study has been completed.
Sponsor:
Information provided by:
Pharmaceutical Research Network
ClinicalTrials.gov Identifier:
NCT00304785
First received: March 17, 2006
Last updated: October 23, 2007
Last verified: October 2007

March 17, 2006
October 23, 2007
May 2005
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00304785 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Latanoprost Versus Fotil
Not Provided

To compare the intraocular pressure effect and safety of latanoprost 0.005% given every evening versus PTFC given twice daily.

Not Provided
Interventional
Phase 4
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double-Blind
Primary Purpose: Treatment
  • Open-Angle Glaucoma
  • Ocular Hypertension
  • Drug: latanoprost 0.005%
  • Drug: Fotil
  • Drug: placebo
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
36
October 2007
Not Provided

Inclusion Criteria:

  • adults with primary open-angle or pigment dispersion glaucoma, or ocular hypertension
  • untreated intraocular pressure should be between 24-36 mm Hg inclusive
  • visual acuity should be 5/50 or better in both eyes

Exclusion Criteria:

  • presence of exfoliation syndrome or exfoliation glaucoma
  • contraindications to study medications
  • any anticipated change in systemic hypotensive therapy
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Poland
 
NCT00304785
PRN 03-026
Not Provided
Not Provided
Pharmaceutical Research Network
Not Provided
Study Director: William C. Stewart, MD Pharmaceutical Research Network, LLC
Principal Investigator: Józef Kałużny, Professor Gabinety Okulistyczne
Principal Investigator: Krystyna Pecold, Professor Kierownik Kliniki Okulistycznej Akademii Medycznej
Principal Investigator: Roman Sobecki, Dr. n.med. Ordynator Oddziału Okulistycznego Międzyleski Szpital Specjalistyczny
Principal Investigator: Krystyna Czechowisz-Janicka, Professor Instytut Jaskry
Principal Investigator: Dariusz Kecik, Professor Katdra Klinika Okulityki Akademii Medycznej w Warszawie
Pharmaceutical Research Network
October 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP